RxDoctor Payments Data

Zu Zhang, MD

Family Medicine · Chamblee, GANPI 1194935510

Payments from drug & device makers

$3,665in general payments, 2019–2025

Across 136 payments — averaging $26.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$496
  • Biohaven Pharmaceuticals, Inc.$483
  • Lilly USA, LLC$372
  • Novo Nordisk$288
  • Abbott$233
  • Amgen$205
  • plus $2K from 22 others

What the payments were for

  • Food & beverage$3,56397%
  • Education$1023%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,665 in reported general payments places this provider in the 80th percentile of 3,111 family medicine providers in Georgia.

See all family medicine providers in Georgia

Medicare billing

Part B allowed, 2024
$271,593
Medicare patients
305
Services billed
7,285

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TrulicityDulaglutide20$46,502
EliquisApixaban32$40,981
Trelegy ElliptaFluticasone/Umeclidin/Vilanter41$38,519
OzempicSemaglutide20$37,848
JardianceEmpagliflozin18$30,630
Janumet XrSitagliptin Phos/Metformin Hcl12$7,544
Tresiba Flextouch U-100Insulin Degludec11$4,378
Lidocaine34$3,358
Albuterol Sulfate HfaAlbuterol Sulfate62$2,006
Lantus SolostarInsulin Glargine,hum.Rec.Anlog17$1,832
Omega-3 Acid Ethyl Esters20$1,793
Diclofenac Sodium47$1,410
Nifedipine ErNifedipine16$1,079
Atorvastatin Calcium194$989
Amlodipine Besylate222$979

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity$372$46,50220 claims
GSKTrelegy Ellipta$88$38,51941 claims
Novo NordiskOzempic$288$37,84820 claims
Boehringer IngelheimJardiance$54$30,63018 claims
MerckJanumet Xr$16$7,54412 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 3,111 family medicine providers in Georgia.

Other family medicine in Chamblee

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →